CGTX Logo

Cognition Therapeutics, Inc. (CGTX) 

NASDAQ
Market Cap
$20.28M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
315 of 776
Rank in Industry
187 of 433

Largest Insider Buys in Sector

CGTX Stock Price History Chart

CGTX Stock Performance

About Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of …

Insider Activity of Cognition Therapeutics, Inc.

Over the last 12 months, insiders at Cognition Therapeutics, Inc. have bought $9,975 and sold $0 worth of Cognition Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Cognition Therapeutics, Inc. have bought $3.75M and sold $4,818 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Ricciardi Lisa (CEO & President) — $19,950.

The last purchase of 5,700 shares for transaction amount of $9,975 was made by Ricciardi Lisa (CEO & President) on 2024‑03‑14.

List of Insider Buy and Sell Transactions, Cognition Therapeutics, Inc.

2024-03-14PurchaseCEO & President
5,700
0.0172%
$1.75$9,975+2.79%
2022-11-29Purchasedirector
10,000
0.0453%
$2.65$26,550-29.84%
2022-11-28Purchasedirector
16,064
0.0706%
$2.65$42,565-31.76%
2022-11-28Purchasedirector
16,064
0.0706%
$2.65$42,565-31.76%
2022-11-16Purchasedirector
71,000
0.3069%
$1.40$99,400+27.37%
2022-11-16Purchasedirector
71,000
0.3069%
$1.40$99,400+27.37%
2022-11-15Purchasedirector
1.5M
5.2511%
$1.20$1.8M+20.34%
2022-11-15Purchasedirector
1.5M
5.2511%
$1.20$1.8M+20.34%
2022-11-15Purchasedirector
12,500
0.0438%
$1.20$15,000+20.34%
2022-11-15PurchaseCEO & President
12,000
0.0455%
$1.30$15,600+20.34%
2021-10-13Sale10 percent owner
74.05
0.0014%
$12.00$889-76.39%
2021-10-13Sale10 percent owner
33.09
0.0006%
$12.00$397-76.39%
2021-10-13Saledirector
23.48
0.0004%
$12.00$282-76.39%
2021-10-13Saledirector
180.56
0.0034%
$12.00$2,167-76.39%
2021-10-13Sale10 percent owner
90.28
0.0017%
$12.00$1,083-76.39%
2021-10-13Purchasedirector
380,000
7.2005%
$12.00$4.56M-76.39%
2021-10-13Purchase10 percent owner
190,000
3.6003%
$12.00$2.28M-76.39%
2021-10-13PurchaseCEO & President
25,000
0.4737%
$12.00$300,000-76.39%
2021-10-13PurchaseChief Financial Officer
10,000
0.1895%
$12.00$120,000-76.39%
2021-10-13Purchasedirector
3,000
0.0568%
$12.00$36,000-76.39%

Insider Historical Profitability

<0.0001%
Ricciardi LisaCEO & President
291345
0.7259%
$0.5130<0.0001%
Fletcher Aaron G.L.director
2021906
5.038%
$0.5141<0.0001%
Kreis Leslie W.director
2021906
5.038%
$0.5130+5.32%
BIOS Memory SPV I, LP10 percent owner
899905
2.2423%
$0.5111<0.0001%
Wallace Peggydirector
37961
0.0946%
$0.5120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Aigh Capital Management Llc$3.45M4.741.9M-6.94%-$257,675.611.97
The Vanguard Group$1.68M2.3921,680+27.73%+$364,229.41<0.0001
Awm Investment Company Inc$1.18M1.62650,000New+$1.18M0.18
Alyeska Investment Group L P$910,000.001.25500,000New+$910,000.000.01
Timelo Investment Management Inc.$874,839.001.2480,681New+$874,839.001.6
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.